Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

betrixaban

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

- PMLiVE

Amgen’s Imlygic recommended for European approval

First-in-class oncolytic immunotherapy wins CHMP positive opinion

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

- PMLiVE

Boehringer’s Praxbind granted accelerated approved by FDA

Reversal agent for anticoagulant Pradaxa given the nod

EU flag

CHMP recommends 19 new medicines for European approval

Praxbind and Entresto - both fast-tracked - among those to be backed

- PMLiVE

Amgen’s Kyprolis and Blincyto on track for European approval

Double CHMP recommendation backs the myeloma and leukaemia drugs

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

Daiichi Sankyo logo

Daiichi Sankyo licenses clot-busting antibody

New drug TS23 could be more much effective for ischemic stroke

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links